Table 1: Demographics of study participants. HRV, high risk varices; LRV; low risk varices; NRH, nodular regenerative hyperplasia; CHF, congenital hepatic fibrosis; PVT, portal vein thrombosis; OGD, oesophogastroduodenoscopy; MELD, Model for End-stage Liver Disease score; APRI, AST to platelet ratio index; LSM, liver stiffness measurement. Unless otherwise stated, values are median (IQR).

Patient demographics All patients With HRV Without HRV P value
(n = 44) (n = 15) (n = 29)

Age (years; mean ± s.d.)46.7 ± 16.752.1 ± 15.145.5 ± 17.20.219

Gender
 Male (%)21 (48)8 (53)12 (41)0.532
 Female (%)23 (52)7 (47)17 (59)

BMI23.0 (21.0 – 26.0)23.0 (19.8 – 27.0)23.0 (21.0 – 26.0)0.854

Aetiology
 NRH (%)16 (36)6 (40)10 (34)-
 CHF (%)8 (18)0 (0)8 (28)-
 Schistosomiasis (%)6 (14)4 (27)2 (7)-
 Idiopathic (%)6 (14)2 (13)4 (14)-
 PVT (%)5 (11)2 (13)3 (10)-
 Other (%)3 (7)1 (7)2 (7)-
Time to OGD (days)83.5 (30 – 121)63 (36 - 121)94 (29 - 124)0.815

Liver disease Severity
 MELD9.0 (8.0 – 12.0) 9.0 (8.0 – 11.0) 9.0 (8.0 – 12.0) 0.661
 Childs Pugh A (%)38 (86)13 (87)25 (86)0.966
 Childs Pugh B (%)6 (14)2 (13)4 (14)

Fibrosis
 Laennec score at liver biopsy (mean ± s.d.)1.19 ± 1.051.18 ± 1.081.16 ± 1.070.953
 FIB4 3.21 (1.66 – 5.01) 3.17 (1.66 – 5.41)3.07 (1.55 – 4.68)0.541
 APRI0.97 (0.53 – 1.55)0.89 (0.54 – 1.78)0.97 (0.51 – 1.53)0.789
 LSM (kPa)8.7 (6.7 – 11.5)8.9 (4.8 – 10.3)8.6 (7.1 – 11.9)0.438